Globus Medical (GMED) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- $1.34
- Estimate
- $1.10
- Surprise
- +21.9%
- Revenue (period 2026-06-30)
- $789.6M
- Score at report (before → after)
- 7.6 → 7.4/10
Revenue source: xbrl.
How the report landed
Globus Medical (GMED) beat the $1.10 estimate with diluted EPS of $1.34 — a large 21.9% upside surprise. TrendMatrix's engine moved from Buy (Wait) (7.6/10) to Hold at 7.4/10 after the report — the engine's score fell despite the beat.
Where TrendMatrix's rating stands now
TrendMatrix currently rates GMED Hold at 6.7/10.
4 of the last 4 quarters beat the estimate; this quarter's +21.9% surprise compares with a +26.4% four-quarter average. Next scheduled report: 2026-11-05.
What supports the rating
- V7 quality resilience bonus: +0.2 (Q=7.4 in RISK_OFF)
- Sector modifier (Healthcare): +0.5
What argues against it
- Negative momentum
- Momentum score 2.3/10 — below 4.5 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $74.19
- Price target
- $89.81
- Stop
- $70.65
- Upside to target
- +21.1%
- Reward-to-risk
- 3.4:1
The stock trades at 19.0× trailing but 13.7× forward earnings — consensus estimates already build in a substantial earnings recovery.
Risk check: RSI 10 — a level conventionally read as oversold.
Model outputs from TrendMatrix’s engine as of 2026-09-14 — shown for context, not personalized investment advice.
GMED at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Devices
- Market cap
- $9.96B
- P/E (fwd)
- 13.7
- P/E (ttm)
- 19.0
- 52-week range
- $54.15–$101.40
- Off 52-week high
- 26.8%
- RSI (14)
- 10
- Volume vs avg
- 1.30×
- Score today
- 6.7/10